Cargando…
CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer
BACKGROUND: This study investigated the local effect and acute toxicity of irinotecan and capecitabine with concurrent intensity-modulated radiation therapy (IMRT) for the treatment of recurrent rectal cancer without prior pelvic irradiation. METHODS: Seventy-one patients diagnosed with recurrent re...
Autores principales: | Cai, Gang, Zhu, Ji, Palmer, Joshua D, Xu, Ye, Hu, Weigang, Gu, Weilie, Cai, Sanjun, Zhang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353448/ https://www.ncbi.nlm.nih.gov/pubmed/25889149 http://dx.doi.org/10.1186/s13014-015-0360-5 |
Ejemplares similares
-
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
por: Willeke, F, et al.
Publicado: (2007) -
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
por: Zhu, Ji, et al.
Publicado: (2013) -
Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016) -
An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype
por: Guan, Yun, et al.
Publicado: (2019) -
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
por: Zhu, Ji, et al.
Publicado: (2014)